GSK files Nucala for COPD

8th November 2017 Uncategorised 0

GlaxoSmithKline is seeking permission to market its asthma biologic mepolizumab for the treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in the US.

More: GSK files Nucala for COPD
Source: News